Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Non-Current Deferred Tax Liability (2016 - 2017)

Vanda Pharmaceuticals' Non-Current Deferred Tax Liability history spans 4 years, with the latest figure at -$386000.0 for Q4 2017.

  • On a quarterly basis, Non-Current Deferred Tax Liability fell 157.96% to -$386000.0 in Q4 2017 year-over-year; TTM through Dec 2017 was -$386000.0, a 157.96% decrease, with the full-year FY2017 number at -$386000.0, down 157.96% from a year prior.
  • Non-Current Deferred Tax Liability hit -$386000.0 in Q4 2017 for Vanda Pharmaceuticals, down from $666000.0 in the prior quarter.
  • Over the last five years, Non-Current Deferred Tax Liability for VNDA hit a ceiling of $1.1 million in Q4 2015 and a floor of -$386000.0 in Q4 2017.
  • Historically, Non-Current Deferred Tax Liability has averaged $346500.0 across 4 years, with a median of $336000.0 in 2014.
  • Biggest five-year swings in Non-Current Deferred Tax Liability: skyrocketed 18233.33% in 2015 and later tumbled 157.96% in 2017.
  • Tracing VNDA's Non-Current Deferred Tax Liability over 4 years: stood at $6000.0 in 2014, then skyrocketed by 18233.33% to $1.1 million in 2015, then plummeted by 39.45% to $666000.0 in 2016, then plummeted by 157.96% to -$386000.0 in 2017.
  • Business Quant data shows Non-Current Deferred Tax Liability for VNDA at -$386000.0 in Q4 2017, $666000.0 in Q4 2016, and $1.1 million in Q4 2015.